title: RESTEM: a percutaneous coronary intervention 'real world' registry in the drug-eluting stent era.
abstract: Sirolimus-eluting stents (SESs) reduce the rate of in-stent restenosis in selected cases. Their performance in more complex patients and their impact on the final clinical outcome of these patients, however, remains uncertain. RESTEM Registry (REgistro delle PCI in era di STEnt Medicati), a prospective multicenter registry collecting all percutaneous coronary interventions (PCIs) performed over 20 months and monitored up to 2 years, includes 5524 consecutive patients treated with bare metal stent (BMS) (72%), sirolimus-eluting stent (SES) (15%), combined BMS+SES (4%), or other techniques (9%). The combination of death, acute myocardial infarction (AMI), unstable angina and revascularizations had been chosen as primary endpoint. One-year multivariate analysis shows no significant advantage of SES in combined clinical events, a slight benefit in primary endpoint [18.5 vs. 25.0% BMS=odds ratio (OR) 0.78) and revascularizations (13.6 vs. 20.4% BMS=OR 0.74], a consistent advantage when only target vessel revascularizations (TVRs) are considered (5.5 vs. 10.5% BMS=OR 0.52). The two-year adjusted results confirm a significant advantage of SES in TVR (8.3 vs. 13.7% BMS=OR 0.65), a slight benefit for revascularizations (18.3 vs. 25.6% BMS=OR 0.76), without reducing mortality and other clinical events; these data refute the benefit on primary endpoint observed at 12 months (25.8 vs. 32.4% BMS=OR 0.84). After analyzing events recorded during the first and second year follow-up periods separately, the incidence of many of them favors SES in the first year, yet appear independent of the technique utilized in the second. RESTEM results confirming SES's capacity to reduce TVR without reduction of other clinical events, suggest that this advantage is limited to the first year after PCI, and show no evidence of excess of deaths, AMIs and late thrombosis following SES implantation described in recent meta-analyses.
authors.affiliation: Villa Maria Group and Foundation- Lugo di Romagna, Cotignola, Italy. luigicampolo@alice.it
authors.forename: Luigi
authors.initials: L
authors.lastname: Campolo
authors.forename: Paolo
authors.initials: P
authors.lastname: Pantaleo
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Barattoni
authors.forename: Arianna
authors.initials: A
authors.lastname: Berardo
authors.forename: Luca
authors.initials: L
authors.lastname: Ghetti
authors.forename: Danilo
authors.initials: D
authors.lastname: Fusco
authors.forename: Alberto
authors.initials: A
authors.lastname: Cremonesi
authors.forename: Chiara
authors.initials: C
authors.lastname: Grattoni
authors.forename: Alfredo
authors.initials: A
authors.lastname: Marchese
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Pernice
authors.forename: Alessandro
authors.initials: A
authors.lastname: Alberti
authors.forename: Enri
authors.initials: E
authors.lastname: Gliozheni
authors.forename: Carlo
authors.initials: C
authors.lastname: Perucci
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D023903:Coronary Restenosis / Q000517:prevention & control; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents
chemical_list: D020123:Sirolimus